Vistagen Therapeutics Inc... (VTGN)
Vistagen Therapeutics Inc. (VTGN) Stock Price, Analysis & Data
| Bid | 0.18 |
| Market Cap | 11.71M |
| Revenue (ttm) | 1.27M |
| Net Income (ttm) | -69.69M |
| Beta | 0.38 |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.17 |
| P/B (ttm) | 0.29 |
| P/S (ttm) | 9.23 |
| Earnings Date | Aug 14, 2026 |
| Ask | 0.34 |
| Volume | 115,941 |
| Avg. Volume (20D) | 4,063,459 |
| Open | 0.26 |
| Previous Close | 0.26 |
| Day's Range | 0.26 - 0.27 |
| 52-Week Range | 0.20 - 5.14 |
| Analyst | Hold |
| Price Target | 1 (284.62%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherin...
Financial Performance
In 2026, Vistagen Therapeutics's revenue was 1.27M, an increase of 161.11% compared to the previous year's 486K. Earnings were -69.69M, an increase of 35.53%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for VTGN stock is "Hold". The 12-month stock price forecast is 1, which is upside of 284.62% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
